Molecular Biomarker Testing in Kidney Cancer: Integrating Diagnosis, Prediction, and Emerging Renal Tumor Entities
Open Access
Abstract
Background: Kidney tumors comprise a biologically diverse and diagnostically challenging group of neoplasms. Many entities share overlapping morphologic features despite having distinct molecular profiles. Although histomorphology remains the cornerstone of diagnosis, molecular biomarker testing has become increasingly important for accurate classification, recognition of emerging entities, identification of hereditary cancer syndromes, and therapeutic decision-making. Focus of the Review: This narrative review provides a practical, pathology-oriented framework for molecular biomarker testing in kidney tumors. It integrates immunohistochemistry, fluorescence in situ hybridization, polymerase chain reaction-based methods, and next-generation sequencing with morphologic assessment. Particular attention is given to diagnostically relevant alterations involving VHL, TFE3, TFEB, MET, FH, ELOC, and ALK, genes encoding SDH subunits, and components of the mTOR signaling pathway, together with commonly used immunohistochemical surrogates. The prognostic and predictive roles of selected biomarkers, including their potential value in hereditary risk assessment and treatment selection, are also discussed. Practical limitations, such as limited biopsy material, intratumoral heterogeneity, and technical variability, are considered. Conclusions: Molecular biomarker testing is reshaping kidney tumor pathology by supporting an integrated diagnostic approach that complements, rather than replaces, careful morphologic evaluation. Its appropriate use can improve diagnostic accuracy, refine clinical stratification, and facilitate the recognition of emerging renal tumor entities with hereditary or therapeutic relevance. Future developments are expected to include methylation profiling, transcriptomic classifiers, liquid biopsy platforms, and artificial intelligence-assisted interpretation.Keywords
This publication has 122 references indexed in Scilit:
- Renal hemangioblastoma and renal cell carcinoma with fibromyomatous stroma and hemangioblastoma-like areas belong to the spectrum of one entityVirchows Archiv, 2025
- FLCN-mutated eosinophilic renal tumors: clinicopathologic and molecular analysis of five cases highlighting morphologic heterogeneityVirchows Archiv, 2025
- Succinate dehydrogenase deficient renal cell carcinoma frequently expresses GATA3 and L1CAMVirchows Archiv, 2025
- Evaluation of an institutional series of low-grade oncocytic tumor (LOT) of the kidney and review of the mutational landscape of LOTVirchows Archiv, 2023
- GPNMB expression identifies TSC1/2/mTOR‐associated and MiT family translocation‐driven renal neoplasmsThe Journal of Pathology, 2022
- Genetic risk assessment for hereditary renal cell carcinoma: Clinical consensus statementCancer, 2021
- Efficacy of Savolitinib vs Sunitinib in Patients WithMET-Driven Papillary Renal Cell CarcinomaJAMA Oncology, 2020
- Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell CarcinomaJAMA Oncology, 2018
- Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline TestingJAMA, 2017
- Platinum plus bortezomib for the treatment of pediatric renal medullary carcinoma: Two casesPediatric Blood & Cancer, 2017